AbbVie's rising immunology star Skyrizi scores nod from England's cost watchdog

AbbVie's Skyrizi was recommended for second-line use by England's cost watchdog, the National Institute for Health and Care Excellence. (AbbVie)

With longtime immunology blockbuster Humira on the decline, AbbVie is looking to next-gen competitor Skyrizi to chip in. A nod from England's cost watchdog could help.

The National Institute for Health and Care Excellence (NICE) recommended (PDF) Skyrizi as a second-line treatment for severe plaque psoriasis in adults who've failed on conventional treatments such as ciclosporin, methoxotrate and phototherapy.

In its final appraisal, NICE said second-line Skyrizi was more effective for plaque psoriasis than Humira and Johnson & Johnson’s Il-12/23 med Stelara and similar in health benefits to J&J’s Tremfya, a head-to-head IL-23 competitor.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

AbbVie has touted Skyrizi as a cost-effective alternative to its closest immunology rivals. That growing field includes the aging anti-TNF class, IL-23 and IL-12/23 inhibitors, and next-gen IL-17 inhibitors like Novartis’ Cosentyx, Eli Lilly’s Taltz and Bausch Health’s Siliq.

That cost edge is one reason Skyrizi rolled out a pricing plan in April to include an $88,500 first-year price on the new med—inclusive of two starter doses—and $59,000 maintenance doses.

RELATED: AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi

Alongside a price tag that AbbVie said beats out any other biologic for moderate to severe plaque psoriasis, Skyrizi also benefits from a less onerous dosing regimen with maintenance doses delivered every 12 weeks rather than the industry standard four weeks. Those factors taken together could lead to $3 billion in peak sales, according to SVB Leerink analyst Geoffrey Porges, though AbbVie has offered a $5 billion peak forecast of its own.

RELATED: The top 10 drug launches of 2019Skyrizi

Skyrizi has not only proven more cost-effective than some of its competitors but has also beaten them in clinical trials. In June, AbbVie released two-year treatment data for Skyrizi showing 72% of patients saw a 100% improvement in skin clearance over placebo. Skyrizi also worked in relapsed patients, with 84% again achieving clear skin after 16 weeks of treatment.

With such a strong showing from its newest immunology entry, AbbVie has high hopes that the newer drug can absorb many of the patients—and sales—expected to be lost as Humira and its nearly $20 billion in 2018 revenue falls from that lofty peak.

RELATED: AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Soon after Skyrizi’s launch in April, AbbVie reportedly began offering 5% to 10% discounts on Humira in an attempt to secure formulary positioning for Skyrizi. Bernstein analyst Ronny Gal said the push for positioning could upset the apple cart with other immunology players and trigger a “pricing war” with payers.

Gal said further discounts on Humira could be in the works if the drugmaker’s JAK-1 inhibitor candidate upadacitinib is approved by the FDA. AbbVie has already rolled out massive Humira discounts as high as 89% in Europe after the drug lost its patent protection late last year.

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…